DGXQuest Diagnostics Incorporated
Quest Diagnostics Incorporated (DGX) is a diagnostic testing and laboratory services provider, offering a broad range of clinical laboratory tests, genetic testing, and molecular diagnostics. The company’s next catalyst is Oct 21, 2026 — Q3 2026 Earnings Release, which will test the business’s ability to sustain revenue growth and margin expansion amid rising costs and regulatory pressures.
- Revenue grew 11.8% YoY to $11.52B in 2026, with a net margin of 9.5% and free cash flow of $2.47B (TTM).
- Debt-to-equity ratio of 0.86x, with diluted EPS of $2.84, signaling a balance of leverage and profitability.
- The earnings release will be a key test of the company’s ability to maintain its growth trajectory and navigate a competitive landscape.
The schedule
- Wed21Oct
- Tue9Feb
- Wed21Apr
- Wed21Jul
Past
- Sat25Jul
Actual outcome: Bull · $210.25 at outcome
Quest Diagnostics met earnings expectations exactly, reporting an EPS of $2.21. The stock initially surged past the $204 bull target, driven by the solid financial results and positive strategic developments, including the launch of a new AI Companion powered by Google's Gemini and the appointment of a new Chief Strategy and M&A Officer. Although shares later moderated, the in-line earnings and forward-looking AI and leadership announcements validated the bullish thesis.
Quest Diagnostics met earnings expectations exactly, reporting an EPS of $2.21. The stock initially surged past the $204 bull target, driven by the solid financial results and positive strategic developments, including the launch of a new AI Companion powered by Google's Gemini and the appointment of a new Chief Strategy and M&A Officer. Although shares later moderated, the in-line earnings and forward-looking AI and leadership announcements validated the bullish thesis.
- Wed22Apr
Actual outcome: Bear · $194.20 at outcome
Quest Diagnostics delivered a strong beat-and-raise quarter, reporting adjusted EPS of $2.50 against estimates of $2.37 and increasing its full-year 2026 guidance due to resilient testing demand. Despite these positive fundamental results, the stock retreated to the bear floor as the market reacted
Quest Diagnostics delivered a strong beat-and-raise quarter, reporting adjusted EPS of $2.50 against estimates of $2.37 and increasing its full-year 2026 guidance due to resilient testing demand. Despite these positive fundamental results, the stock retreated to the bear floor as the market reacted
- Thu26Feb
Actual outcome: Bull · $206.87 at outcome
Quest Diagnostics delivered a strong bull outcome by beating Q4 2025 EPS and revenue estimates and providing 2026 guidance that exceeded consensus expectations. This strong outlook, which alleviated concerns about PAMA pressure, was reinforced by a 7.5% dividend increase and a $1 billion boost to the share repurchase authorization. The positive fundamental results drove the stock significantly higher, pushing it well past the bull target.
Quest Diagnostics delivered a strong bull outcome by beating Q4 2025 EPS and revenue estimates and providing 2026 guidance that exceeded consensus expectations. This strong outlook, which alleviated concerns about PAMA pressure, was reinforced by a 7.5% dividend increase and a $1 billion boost to the share repurchase authorization. The positive fundamental results drove the stock significantly higher, pushing it well past the bull target.